U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209449) titled 'A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer' on Oct. 01.
Brief Summary: The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Intervention:
DRUG: Abemaciclib
orally only in the evening
DRUG: Elacestrant
orally once daily in the morning
Recruitment Status: RECRUITING
Sponsor: Memorial Sloan Kettering Cancer Center
Published by HT Digital ...